Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
VIROPHARMA INC (VPHM)
|
Add to portfolio |
|
|
|
| Price: |
$20.60
| | Metrics |
| OS: |
65.9
|
M
| |
-9
|
% ROE
|
| Market cap: |
$1.36
|
B
| |
-2
|
% ROIC
|
|
Net cash:
|
$107
|
M
| |
$1.62
|
per share
|
|
EV:
|
$1.25
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$52.0
|
M
| |
24.1
|
x EV/EBITDA
|
|
EBIT
|
$16.8
|
M
| |
74.4
|
x EV/EBIT
|
| EPS |
($0.99)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 427.9 | 544.4 | 439.0 | 310.4 | 232.3 | 203.8 | 167.2 | 132.4 |
| Revenue growth | -21.4% | 24.0% | 41.4% | 33.6% | 14.0% | 21.9% | 26.3% | 491.4% |
| Cost of goods sold | 108.5 | 80.0 | 61.3 | 40.2 | 8.9 | 8.9 | 19.0 | 18.0 |
| Gross profit | 319.4 | 464.4 | 377.7 | 270.2 | 223.4 | 194.8 | 148.2 | 114.4 |
| Gross margin | 74.6% | 85.3% | 86.0% | 87.0% | 96.2% | 95.6% | 88.6% | 86.4% |
| Selling, general and administrative | 174.3 | 127.8 | 95.7 | 89.3 | 67.3 | 39.0 | 24.6 | 10.5 |
| Research and development | 67.7 | 66.5 | 39.6 | 52.1 | 64.4 | 33.9 | 19.2 | 10.6 |
| EBITA | 73.2 | 265.4 | 241.1 | 125.4 | 91.7 | 121.9 | 104.5 | 93.3 |
| EBITA margin | 17.1% | 48.7% | 54.9% | 40.4% | 39.5% | 59.8% | 62.5% | 70.5% |
| Amortization of intangibles | 35.3 | 31.0 | 29.4 | 28.2 | 10.8 | 6.1 | 5.7 | 5.2 |
| EBIT | 37.9 | 234.3 | 211.7 | 97.2 | 80.9 | 115.8 | 98.8 | 88.1 |
| EBIT margin | 8.8% | 43.0% | 48.2% | 31.3% | 34.8% | 56.8% | 59.1% | 66.6% |
| Pre-tax income | 19.0 | 208.0 | 200.9 | 30.0 | 80.0 | 130.4 | 108.5 | 75.9 |
| Income taxes | 13.4 | 67.3 | 75.3 | 41.0 | 16.0 | 38.3 | 41.9 | -37.8 |
| Tax rate | 70.5% | 32.4% | 37.5% | 137.0% | 20.1% | 29.4% | 38.6% | |
| Net income | 5.6 | 140.7 | 125.6 | -11.1 | 64.0 | 92.1 | 66.7 | 113.7 |
| Net margin | 1.3% | 25.8% | 28.6% | -3.6% | 27.5% | 45.2% | 39.9% | 85.9% |
| |
| Diluted EPS | $0.08 | $1.60 | $1.39 | ($0.14) | $0.75 | $1.14 | $0.95 | $1.97 |
| Shares outstanding (diluted) | 71.8 | 88.1 | 90.1 | 77.4 | 85.7 | 80.9 | 70.3 | 57.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|